Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Amiodarone pulmonary toxicity

INTRODUCTION

Amiodarone is an iodinated benzofuran derivative that is highly effective in suppressing ventricular and supraventricular tachyarrhythmias. Adverse side effects are common and include photosensitivity, blue-gray discoloration of the skin, thyroid dysfunction, corneal deposits, abnormal liver function tests, and bone marrow suppression [1]. Pulmonary toxicity is the most serious adverse effect of amiodarone.

The types, pathogenesis, risk factors, diagnosis, and treatment of amiodarone pulmonary toxicity will be reviewed here. The other major side effects of amiodarone are discussed separately. (See "Major side effects of amiodarone".)

TYPES OF DISEASE

Several forms of pulmonary disease occur among patients treated with amiodarone, including chronic interstitial pneumonitis, organizing pneumonia, acute respiratory distress syndrome, and a solitary pulmonary mass. The incidence of pulmonary toxicity from amiodarone is not precisely known but is likely to be approximately 5 percent [2].

A characteristic finding in all patients exposed to amiodarone is the presence of numerous foamy macrophages in the air spaces (picture 1), which are filled with amiodarone-phospholipid complexes (image 1). Like other amphiphilic compounds, amiodarone can cause an accumulation of phospholipids within lysosomes in the lungs and other tissues due to the inhibition of phospholipase A [1]. Ultrastructural studies show myelinoid inclusion bodies in the affected tissue.

Chronic interstitial pneumonitis — Chronic interstitial pneumonitis is the most common presentation of amiodarone-induced pulmonary disease. It is characterized by the insidious onset of nonproductive cough, dyspnea, and weight loss. The chest radiograph reveals focal or diffuse interstitial opacities. Interstitial pneumonitis is usually recognized after two or more months of therapy, especially in patients in whom the dose of amiodarone exceeds 400 mg per day [3]. These manifestations are due to a nonspecific interstitial pneumonitis predominantly composed of mononuclear cells, foamy alveolar macrophages, type II cell hyperplasia, and fibrosis. Various forms of lymphocytic infiltration of the lungs have been described, including diffuse lymphoid hyperplasia, follicular bronchiolitis, and lymphoid interstitial pneumonia [4].

                      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2014. | This topic last updated: Jan 7, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Mason JW. Amiodarone. N Engl J Med 1987; 316:455.
  2. Jackevicius CA, Tom A, Essebag V, et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol 2011; 108:705.
  3. Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest 1988; 93:1067.
  4. Larsen BT, Vaszar LT, Colby TV, Tazelaar HD. Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. Am J Surg Pathol 2012; 36:509.
  5. Dean PJ, Groshart KD, Porterfield JG, et al. Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol 1987; 87:7.
  6. Valle JM, Alvarez D, Antúnez J, Valdés L. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare aetiology. Eur Respir J 1995; 8:470.
  7. Zitnik, RJ. Drug-induced lung disease: Antiarrhythmic agents. J Respir Dis 1996; 17:254.
  8. Greenspon AJ, Kidwell GA, Hurley W, Mannion J. Amiodarone-related postoperative adult respiratory distress syndrome. Circulation 1991; 84:III407.
  9. Kay GN, Epstein AE, Kirklin JK, et al. Fatal postoperative amiodarone pulmonary toxicity. Am J Cardiol 1988; 62:490.
  10. Van Mieghem W, Coolen L, Malysse I, et al. Amiodarone and the development of ARDS after lung surgery. Chest 1994; 105:1642.
  11. Wood DL, Osborn MJ, Rooke J, Holmes DR Jr. Amiodarone pulmonary toxicity: report of two cases associated with rapidly progressive fatal adult respiratory distress syndrome after pulmonary angiography. Mayo Clin Proc 1985; 60:601.
  12. Iskandar SB, Abi-Saleh B, Keith RL, et al. Amiodarone-induced alveolar hemorrhage. South Med J 2006; 99:383.
  13. Vizioli LD, Cho S. Amiodarone-associated hemoptysis. Chest 1994; 105:305.
  14. Borders CW 3rd, Bennett S, Mount C, Claassen SL. A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. Mil Med 2012; 177:118.
  15. Tanawuttiwat T, Harindhanavudhi T, Hanif S, Sahloul MZ. Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication. Heart Lung Circ 2010; 19:435.
  16. Azzam I, Tov N, Elias N, Naschitz JE. Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge. Postgrad Med J 2006; 82:73.
  17. Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 1988; 93:1242.
  18. Seki S, Itagaki S, Kobayashi M, et al. Amiodarone increases the accumulation of DEA in a human alveolar epithelium-derived cell line. Biol Pharm Bull 2008; 31:1449.
  19. Yano T, Itoh Y, Yamada M, et al. Combined treatment with L-carnitine and a pan-caspase inhibitor effectively reverses amiodarone-induced injury in cultured human lung epithelial cells. Apoptosis 2008; 13:543.
  20. Lee KY, Oh S, Choi YJ, et al. Activation of autophagy rescues amiodarone-induced apoptosis of lung epithelial cells and pulmonary toxicity in rats. Toxicol Sci 2013; 136:193.
  21. Kosseifi SG, Halawa A, Bailey B, et al. Reduction of amiodarone pulmonary toxicity in patients treated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ther Adv Respir Dis 2009; 3:289.
  22. Akoun GM, Gauthier-Rahman S, Milleron BJ, et al. Amiodarone-induced hypersensitivity pneumonitis. Evidence of an immunological cell-mediated mechanism. Chest 1984; 85:133.
  23. Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol 2008; 66:82.
  24. Range FT, Hilker E, Breithardt G, et al. Amiodarone-induced pulmonary toxicity--a fatal case report and literature review. Cardiovasc Drugs Ther 2013; 27:247.
  25. Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002; 89:896.
  26. Pfeil MN, Vollenweider P, Fitting JW. Fatal pulmonary toxicity after a short course of amiodarone therapy. Clinical Geriatrics 2012; 20:34.
  27. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82:51.
  28. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.
  29. Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007; 71:1610.
  30. Singh SN, Fisher SG, Deedwania PC, et al. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J Am Coll Cardiol 1997; 30:514.
  31. Olshansky B, Sami M, Rubin A, et al. Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. Am J Cardiol 2005; 95:404.
  32. Mason JW. Prediction of amiodarone-induced pulmonary toxicity. Am J Med 1989; 86:2.
  33. Gleadhill IC, Wise RA, Schonfeld SA, et al. Serial lung function testing in patients treated with amiodarone: a prospective study. Am J Med 1989; 86:4.
  34. Endoh Y, Hanai R, Uto K, et al. KL-6 as a potential new marker for amiodarone-induced pulmonary toxicity. Am J Cardiol 2000; 86:229.
  35. Standertskjöld-Nordenstam CG, Wandtke JC, Hood WB Jr, et al. Amiodarone pulmonary toxicity. Chest radiography and CT in asymptomatic patients. Chest 1985; 88:143.
  36. Kuhlman JE, Teigen C, Ren H, et al. Amiodarone pulmonary toxicity: CT findings in symptomatic patients. Radiology 1990; 177:121.
  37. Xaubet A, Roca J, Rodriguez-Roisin R, et al. Bronchoalveolar lavage cellular analysis and gallium lung scan in the assessment of patients with amiodarone-induced pneumonitis. Respiration 1987; 52:272.
  38. Ohar JA, Jackson F, Dettenmeier PA, et al. Bronchoalveolar lavage cell count and differential are not reliable indicators of amiodarone-induced pneumonitis. Chest 1992; 102:999.
  39. Coudert B, Bailly F, Lombard JN, et al. Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature. Chest 1992; 102:1005.
  40. De Ferrari GM, Dusi V. Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf 2012; 11:1023.
  41. Okayasu K, Takeda Y, Kojima J, et al. Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse. Intern Med 2006; 45:1303.
  42. Sato N, Kojima K, Horio Y, et al. Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion. Chest 2013; 143:1146.
  43. Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 1987; 18:349.